Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAB-23E73 in KRAS-altered advanced solid tumors
NCT06959615Phase 2Recruiting
- Sponsor
- Jacobio Pharmaceuticals
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JAB-23E73 in solid tumor (advanced stage), sponsored by Jacobio Pharmaceuticals. Started Nov 2024; status: recruiting.
02
Drugs
JAB-23E73
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06959615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06959615.